Experience of Uncommon EGFR Mutation in Lung Scheme Quality Program: Discussing Risks and Opportunities for the Improvement of Laboratory Response
Background The quality programs can be considered to be a valuable tool for global and individual growth. Each result, obtained by a single laboratory, contributes to define the standardization of the response. In the case of the uncommon epidermal growth factor receptor (EGFR) mutations, the molecu...
Guardado en:
Autores principales: | Alessandro Pancrazzi, Agostino Ognibene, Alice Moncada, Valerio Torre |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Georg Thieme Verlag KG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/db65eb245f784111913ef238de4903be |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
por: Kate S, et al.
Publicado: (2019) -
Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique
por: Yangchun Gu, et al.
Publicado: (2021) -
RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
por: Chaido Sirinian, et al.
Publicado: (2021) -
Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
por: Chin‐Chou Wang, et al.
Publicado: (2021) -
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Akiko Takahashi, et al.
Publicado: (2018)